Table 2: Relapsed/refractory immunochemotherapy for CLL patients.

TrialRegiments CROROS (months)Median PFS (months)

Robak et al. [25]RC1813%67%ND12
versus RCC289%78%ND12
Robak et al. [26]FC27613%58%4620.6
versus RFC27624.3%69.6%6430.6
Castro et al. [27]Rituximab HDMP1436%93%NDND
Wierda [28]Ofatumumab, FA-ref,950%51%14.25.5
versus ofatumumab, BF-ref1112%54%17.45.5
Gritti et al. [29]Alemtuzumab188%44%ND14.6
Zent et al. [30]PAR1932%74%237
Badoux et al. [31]CFAR3129%65%117
O’Brien et al. [32]FC1209%17%346
versus FC-oblimersen1213%7%339
Chen et al. [33]Lenalidomide250%56%2424

: number of patients in the trial, CR: complete response, OR: overall response, OS: overall survival, PFS: progression-free survival, ND: no data, FC: fludarabine and cyclophosphamide, RFC: rituximab, fludarabine, and cyclophosphamide, RC: rituximab, cladribine and RCC: rituximab, cladribine, and cyclophosphamide, PAR: pentostatin, alemtuzumab, and rituximab, CFAR: cyclophosphomide, fludarabine, alemtuzumab, and rituximab, HDMP: high-dose methylprednisolone, BF-ref: fludarabine refractory, FA-ref: fludarabine and alemtuzumab refractory.